Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 940567 | Other Grant/Funding Number | American Heart Association |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| American Heart Association | OTHER |
Not provided
Not provided
Not provided
Not provided
In this study, we are trying to see if vitamin B6 can minimize the amplified blood pressure response to exercise following ischemia-reperfusion injury. We are interested in a protein called P2X3, of which function can be blocked by vitamin B6, in the neurons of our nervous system. It is very important for blood pressure regulation. We would like to see if the P2X3 plays a role in patients' rising blood pressure during exercise. The results of the proposed studies will provide a base for those two potential economic and non-invasive inventions to improve the overall health and well-being of PAD patients.
The Ischemia-reperfusion (IR) injury is caused by a burst of reactive oxygen species (ROS) production during reperfusion, which leads to cell damage and inflammation and further exacerbates the underlying ischemic condition. PAD patients endure this pathological condition during various situations of this disease. In a hindlimb IR model, the blood flow in the lower extremity of the plantar muscle and gastrocnemius muscle reduced at 6 h after the femoral artery ligation and gradually restores at 18, 66 and 114 h after the blood flow reperfusion in the femoral artery. Meanwhile, the mean arterial pressure (MAP) responses to static muscle contraction increased in the above blood reperfusion time courses. Examining the underlying mechanisms leading to the exaggerated EPR in the IR injury of PAD will be essential to provide a fundamental base for developing effective interventions to prevent or alleviate the PAD-associated symptoms and complications. The P2X3 receptor in DRG is a potential candidate for regulating this exaggerated EPR in IR. Vitamin B6 can function as a blockade for the P2 receptors. Therefore, we hypothesize it will attenuate the exaggerated exercise pressor reflex (EPR) in the experimental lower limb IR procedure on healthy human participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator |
| |
| Vitamin B6 25mg | Active Comparator |
| |
| Vitamin B6 50mg | Active Comparator |
| |
| Vitamin B6 100mg | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vitamin B6 25 MG | Drug | Vitamin B6 25 mg/day will be given for up to 31 days. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| baseline blood pressure in mmHg | Recorded continuously for up to 4 hours during the study visit | |
| Second visit blood pressure in mmHg | Recorded continuously for up to 4 hours during the second study visit (up to 31 day after the first visit)) | |
| baseline heart Rate in beats per minute | Recorded continuously for up to 4 hours during the study visit | |
| Second visit heart Rate in beats per minute | Recorded continuously for up to 4 hours during the second study visit (up to 31 day after the first visit)) | |
| baseline muscle sympathetic nerve activity in burst/min | Recorded continuously for up to 4 hours during the study visit | |
| Second visit muscle sympathetic nerve activity in burst/min | Recorded continuously for up to 4 hours during the second study visit (up to 31 day after the first visit)) | |
| baseline walking time in minutes | Recording walking time to fatigue (up to 22 minutes maximum) during the study visit | |
| Second visit walking time in minutes | Recording walking time to fatigue (up to 22 minutes maximum) during the second visit (up to 31 days after the first visit)) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lu Qin, PhD | Contact | 7175317483 | lqin@pennstatehealth.psu.edu | |
| Kris Gray, MS | Contact | 7175314589 | kgray1@pennstatehealth.psu.edu |
| Name | Affiliation | Role |
|---|---|---|
| Lu Qin | Penn State College of Medicine | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D015427 | Reperfusion Injury |
| D058729 | Peripheral Arterial Disease |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D025101 | Vitamin B 6 |
| ID | Term |
|---|---|
| D010847 | Picolines |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Vitamin B6 50 MG |
| Drug |
Vitamin B6 50 mg/day will be given for up to 31 days. |
|
| Vitamin B6 100 MG | Drug | Vitamin B6 100 mg/day will be given for up to 31 days. |
|
| Placebo | Drug | Placebo capsule will be given for up to 31 days. |
|
| D013568 | Pathological Conditions, Signs and Symptoms |
| D050197 | Atherosclerosis |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D016491 | Peripheral Vascular Diseases |